Overexpression of SOCS-2 and SOCS-3 genes reverses erythroid overgrowth and IGF-I hypersensitivity of primary polycythemia vera (PV) cells

Leukemia and Lymphoma

Volumn 48, Issue 1, 2007, Pages 134-146

  Usenko, Tatiana ^a   Eskinazi, Denise ^a,b   Correa, Paulo ^c   Amato, Dominick ^d   Ben David, Yaacov ^a,b   Axelrad, Arthur ^a,d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Biogrowth Co   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; JANUS KINASE 2; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; SOCS2 PROTEIN, HUMAN; SOCS3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ERYTHROID PRECURSOR CELL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HYPERSENSITIVITY REACTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; CELL PROLIFERATION; COMPARATIVE STUDY; DRUG EFFECT; ERYTHROID CELL; GENETIC TRANSFECTION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; ERYTHROID CELLS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; POLYCYTHEMIA VERA; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 34247265497     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601043138     Document Type: Article

References (44)

1. Adamson, J. W., Fialkow, P. J., Murphy, S., Prchal, J. F. and Steinmann, L. (1976) Polycythemia vera: Stem cell and probable clonal origin of the disease. New Engl J Med, 295, pp. 913-916.
2. Golde, D. W. and Cline, M. J. (1976) Pathogenesis of polycythemia vera - new concepts. Am J Hematol, 1, pp. 351-355.
3. Spivak, J. L. (2002) Polycythemia vera: Myths, mechanisms, and management. Blood, 100, pp. 4272-4290.
4. Vaquez, H. Sur une forme speciale de cyanose s'accompagnant d'hyperglobulie excessive et persistante. Comptes Rendus de la Societ d Biologie (Paris), 44, pp. 384-388.
5. Osler, W. (1903) Chronic cyanosis, with polycythemia and enlarged spleen: A new clinical entity. Am J Med Sci, 126, pp. 176-201.
6. Berlin, N. I. (1974) Diagnosis and classification of the polycythemias. Semin Hematol, 12, pp. 339-351.
7. Spivak, J. L., Pham, J., Isaacs, M. and Hankins, W. D. (1991) Erythropoietin is both a mitogen and a survival factor. Blood, 77, pp. 1228-1233.
8. de Klerk, G., Rosengarten, P. C., Vet, R. J. and Goudsmit, R. (1981) Serum erythropoietin (ESF) titer in polycythemia. Blood, 58, pp. 1171-1174.
9. Carneskog, J., Kutti, J., Wadenvik, H., Lundberg, P. A. and Lindstedt, G. (1998) Plasma erythropoietin by high detectability immunoradiometric assay in untreated and treated patients with polycythemia vera and essential thrombocythemia. Eur J Haematol, 60, pp. 278-282.
10. Prchal, J. F. and Axelrad, A. A. (1974) Bone-marrow responses in polycythemia vera. New Engl J Med, 290, p. 1382.
11. Fisher, M. J., Prchal, J. F., Prchal, J. T. and D'Andrea, A. D. (1994) Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood, 84, pp. 1982-1991.
12. Correa, P. N., Eskinazi, D. and Axelrad, A. A. (1994) Circulating erythroid progenitors in Polycythemia vera are hypersensitive to IGF-I in vitro: Studies in an improved serum-free medium. Blood, 83, pp. 99-112.
13. Axelrad, A. A. (2004) Growth factor signaling in Polycythemia vera cells: Specific hypersensitivities to cytokines in the chronic myeloproliferative disorders. Molecular Basis of Chronic Myeloproliferative Disorders, pp. 65-73. Springer-Verlag, Berlin
14. Werther, G. A., Haynes, K. and Johnson, G. R. (1990) Insulin-like growth factors promote DNA synthesis and support cell viability in fetal hemopoietic tissue by paracrine mechanisms. Growth Factors, 3, pp. 171-179.
15. Roith, D Le, Werner, H., Beitner-Johnson, D. and Roberts Jr, C. T. (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev, 16, pp. 143-163.
16. Muta, K. and Krantz, S. B. (1993) Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor I as well as by erythropoietin. J Cell Physiol, 156, pp. 264-271.
17. Peruzzi, F., Prisca, M., Dews, M., Salomoni, P., Grassilli, E. and Romano, G. (1999) Multiple signaling pathways of the insulin-like growth factor I receptor in protection from apoptosis. Mol Cell Biol, 19, pp. 7203-7215.
18. Baserga, R., Hongo, A., Rubini, M., Prisco, M. and Valentinis, B. (1997) The IGF-I receptor in cell growth, transformation and apoptosis. Biochem Biophys Acta, 1332, pp. F105-F126.
19. Valentinis, B., Romano, G., Peruzzi, F., Morrione, A., Prisco, M. and Soddu, S. (1999) Growth and differentiation signals by the insulin- like growth factor-I receptor in hemopoietic cells are mediated through different pathways. J Biol Chem, 274, pp. 12423-12430.
20. Mirza, A. M., Correa, P. N. and Axelrad, A. A. (1995) Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor I receptor β subunit in circulating mononuclear cells of patients with Polycythemia vera. Blood, 86, pp. 877-882.
21. James, C., Ugo, V. and Couedic, J Le (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, pp. 1144-1148.
22. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N. and Swanton, S. (2005) Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, pp. 1054-1061.
23. Levine, R. L., Wadleigh, M., Cools, J., Ebert, B., Wernig, G. and Huntly, B. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, pp. 387-397.
24. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S., Tiedt, R. and Passweg, J. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 352, pp. 1779-1790.
25. Axelrad, A. A., Eskinazi, D., Correa, P. N. and Amato, D. (2000) Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHuMGDF) in essential thrombocythemia. Blood, 96, pp. 3310-3321.
26. Axelrad, A. A., Eskinazi, D. and Amato, D. (1999) Does hypersensitivity of progenitor cells to normal cytokine(s) play a role in the pathogenesis of idiopathic myelofibrosis with myeloid metaplasia?. Blood, 94, p. 2886.
27. Staerk, J., Kallin, A., Demoulin, J. B., Vainchenker, W. and Constantinescu, S. N. (2005) JAK1 and Tyk2 activation by the homologous Polycythemia vera JAK2 V617F mutation: Cross talk with IGFI receptor. J Biol Chem, 280, pp. 41893-41899.
28. Kralovics, R., Stockton, D. W. and Prchal, J. T. (2003) Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood, 102, pp. 3793-3796.
29. Kovanen, P. E. and Leonard, W. J. (1999) Inhibitors keep cytokines in check. Curr Biol, 9, pp. R899-R902.
30. Krebs, D. L. and Hilton, D. J. (2000) SOCS: Physiological suppressors of cytokine signaling. J Cell Sci, 113, pp. 2813-2819.
31. Hilton, D. J., Richardson, R. T., Alexander, W. S., Viney, E. M., Willson, T. A. and Sprigg, N. S. (1998) Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA, 95, pp. 114-119.
32. Zhang, J. G., Farley, A., Nicholson, S. E., Willson, T. A., Zugaro, L. M. and Simpson, R. J. (1999) The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA, 96, pp. 2071-2076.
33. Rui, L., Yuan, M., Frantz, D., Shoelson, S. and White, M. F. (2002) SOCS1 and SOCS3 block signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem, 277, pp. 42394-42398.
34. Emanuelli, B., Peraldi, P., Filloux, C., Sowka-Verhelle, D., Hilton, D. and Van Obberghen, E. (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem, 275, pp. 15985-15991.
35. Correa, P. N. and Axelrad, A. A. (1991) Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: Role of IGF-I. Blood, 78, pp. 2823-2833.
36. Zong, C. S., Chan, J., Levy, D. E., Horvath, C., Sadowski, H. B. and Wang, L. H. (2000) Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem, 275, pp. 15099-15105.
37. Roder, S., Steimle, C., Meinhardt, G. and Pahl, H. L. (2001) STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp Hematol, 29, pp. 694-702.
38. Dey, B. R., Spence, S. L., Nissley, P. and Furlanetto, R. W. (1998) Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J Biol Chem, 273, pp. 24095-24101.
39. Magrangeas, F., Boisteau, O., Denis, S., Jasques, Y. and Minvielle, S. (2001) Negative cross-talk between interleukin-3 and interleukin-11 is mediated by suppressor of cytokine signalling-3 (SOCS-3). Biochem J, 353, pp. 223-230..
40. Greenhalgh, C. J., Metcalf, D., Thaus, A. L., Corbin, J. E., Uren, R. and Morgan, P. O. (2002) Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem, 277, pp. 40181-40184.
41. Ram, P. A. and Waxman, K. J. (1999) SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem, 274, pp. 35553-35561.
42. Adams, T. E., Hansen, J. A., Starr, R., Nicola, N. A., Hilton, D. J. and Billestrup, N. (1998) Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J Biol Chem, 273, pp. 1285-1287.
43. Favre, H., Benhamou, A., Finidori, J., Kelly, P. A. and Edery, M. (1999) Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett, 453, pp. 63-66.
44. Goldshmit, Y., Walters, C. E., Scott, H. J., Greenhalgh, G. J. and Turnley, A. M. (2004) SOCS 2 induces neurite outgrowth by regulation of EGF receptor activation. J Biol Chem, 279, pp. 16349-16355.